You are here

Annual ART Costs Far Outpace Inflation Rate, 2012-2018

Wednesday, February 12, 2020

TargetHIV

The average annual costs of HIV ART regimens have escalated in recent years, with the average annual price of recommended ART regimens having jumped 34% since 2012 or 3.5 times the inflation rate. This finding (and more) is summarized in HIV Antiretroviral Therapy Costs in the United States, 2012-2018, a JAMA Network Research Letter. Note: (Access to the JAMA article requires sign-in or an account.)

The review takes Average Wholesale Price (AWP), a rather imprecise measure of costs actually incurred by both patients and insurers, given the plethora of rebates, discounts, and negotiated prices. Regardless, the data do provide a rough insight into what it will take to expand access to HIV therapy in order to end the HIV epidemic.

Learn more about Ryan White Part B AIDS Drug Assistance Programs (ADAPs) and how they are managing access and costs of HIV-related regimens for persons with little to no access to needed services, including HRSA-funded ADAP Technical Assistance

Total views: 101